Kornimate/medical-research-clean huggingface dataset:
non-invasive transcranial electrical stimulation in ms

Conditions: Multiple Sclerosis; Cognitive Impairment

Summary: the goal is to investigate the effects of non-invasive transcranial electrical stimulation on cognition in ms.

the participants' baseline cognitive function will be assessed with a tablet-based, videogame-like software specifically designed as a medical device to test and train cognitive function for populations with cognitive disorders. after baseline test assessment, participants will receive stimulation while playing the training version of the software. after the stimulation, cognitive performance will be evaluated again with the testing version. investigators will assess changes in cognitive performance associated with stimulation.

Eligibility criteria:
inclusion criteria: * age 18-65, * diagnosis of ms * expanded disability status scale (edss)≤6.5, no paresis of the upper limbs * a minimum of 3 months since the last relapse * beck depression inventory\<19 * normal hearing * and no changes in ms or symptomatic medications in past 2 months exclusion criteria: * prior brain surgery * clips in brain * epilepsy or other neurological or non-affective psychiatric disorders * pregnancy
comparison of the clinical response of total neoadjuvant treatment of two methods of long-term or short-term chemoradiotherapy in rectal cancer

Conditions: Locally Advanced Rectal Carcinoma

Summary: rectal cancer is one of the most prevalent malignancies in the world, and its prevalence is rising. in more advanced cases neoadjuvant therapy is advised before to surgery, and radiotherapy is one of its cornerstones. for the treatment of rectal cancer, there are primarily two radiation techniques. long-term radiotherapy is 50.4 gy delivered in 28 fractions, while short-term radiotherapy is 25 gy delivered in 5 parts. in earlier studies, these two radiation techniques were combined with various chemotherapy drugs, and a relative comparison was established. total neoadjuvant treatment, or tnt, has been linked to a better outcome because of the significance of organ preservation. the aim of this research is to compare two tnt radiation techniques with the same regimen of treatment.


Eligibility criteria:
inclusion criteria: locally advanced (t3-4, n+)adenocarcinoma of rectum that is located 5 to 15 cm from anal verge . exclusion criteria: familial syndromes e.g. lynch previous history of cancer previous history of chemotherapy recurrent disease metastatic disease inability to perform mri (claustrophobia or prosthetic valve)
acupuncture for relief of gag reflex

Conditions: Gagging During Transesophageal Echocardiography

Summary: the aim of the study is to test whether stimulation of acupuncture points cv24 and p6 is better than placebo acupuncture in treatment of gagging in patients undergoing elective transesophageal echocardiography (tee)

patients undergoing elective transesophageal echocardiography (tee) often report discomfort because of active gagging reflex, which sometimes preclude the performance of tee and requires additional medication. according to existing literature, needling of acupoint cv24 effectively prevents gagging during dental procedures. we are going to use this phenomenon in patients scheduled to tee in order to reduce discomfort during insertion of tee probe and reduce the need for additional sedative medication. within this investigation the patients will be randomly assigned to receive either verum acupuncture of cv24 and p6 acupoints or placebo procedure immediately before tee examination. as outcome the incidence and intensity of gagging, total dose of additional sedative medication and hemodynamic parameters will be recorded.

Eligibility criteria:
inclusion criteria: 1. patients with an american society of anesthesiologists physical status of i to iii scheduled for elective ambulatory transesophageal echocardiography (tee) without sedation 2. tee time does not exceed 30 minutes 3. patients without previous opioid and psychotropic medication 4. patients aged between 30 and 65 years, able to use visual analogue scale 100 mm 5. patients who have given written informed consent exclusion criteria: 1. current psychiatric disease 2. local skin infection at the sites of acupuncture 3. aged \ 65 years 4. tee time more than 30 min 5. patients who consumed opioid medication at least 6 months before surgery 6. patients with the history of: i) psychiatric disease; ii) insulin-dependent diabetes mellitus; iii) radio- or chemotherapy; iv) peripheral polyneuropathy. 7. patients who are unable to understand the consent form or to use visual analogue scale 100 mm
determination of muscle strength in parkinsonian patients through the use of an isokinetic dynamometer

Conditions: Parkinson's Disease

Summary: decreased muscle strength has been reported to be a factor contributing to increased incidences of falling in the elderly patients causing fractures, joint dislocations, severe soft tissue lesions and head trauma. parkinson's disease (pd) patients often complain of weakness and it has been reported that they have reduced muscle strength, decreased rate of force development, impaired ability to maintain constant force, and increased muscle coactivation during balance perturbation tasks. the specific cause of this weakness is not known, and in this study the investigators have analyzed and measured isokinetic muscle strength in pd patients to clarify this issue. the investigators have compared the data obtained with those of age-matched controls.

an isokinetic muscle action is defined by its performance at a constant speed or velocity. the laboratory measurements of isokinetic strength provides torque measurements throughout the active range of motion during a maximal effort. torque is the force rotating about an axis and is produced and recorded from the angular motion. consequently, the peak torque is an index of the muscular strength. isokinetic testing was introduced as a quantitative measurement of both statistic and dynamic muscular contraction in which all variables involved (resistance, limb velocity, joint position) are under control. this is because isokinetic muscle testing allows objective, valid, and reliable measurement of the force produced by skeletal muscle during exercise at constant velocity and accommodating resistance and it is appropriate for measuring muscle strength and muscle endurance across the disability spectrum. decreased muscle strength has been reported to be a factor contributing to increased incidences of falling in the elderly patients causing fractures, joint dislocations, severe soft tissue lesions and head trauma. parkinson's disease (pd) patients often complain of weakness and it has been reported that they have reduced muscle strength, decreased rate of force development, impaired ability to maintain constant force, and increased muscle coactivation during balance perturbation tasks. the specific cause of this weakness is not known, and in this study the investigators have analyzed and measured isokinetic muscle strength in pd patients to clarify this issue. the investigators have compared the data obtained with those of age-matched controls.

Eligibility criteria:
inclusion criteria: * pd in stage 2-3 of hoen\&yahr according to the united kingdom brain bank criteria. exclusion criteria: * atypical parkinsonisms * pd patients with relevant orthopedic * rheumatic and muscular conditions

Keywords: strength in pd patients isokinetic muscle strength
analysis of primary and metastatic tumors in patients with renal cell carcinoma and urothelial carcinoma

Conditions: Renal Cell Carcinoma; Urothelial Carcinoma; Bladder Cancer; Ureter Cancer; Urethral Cancer

Summary: this is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (icb) treatment targting programmed cell death 1 (pd1) but developed new lesions later were also removed and stored in the biosample repository (bsr). the histology and genomic analysis of the pre-treatment and metastatic samples from the same patient would be used to find out the changes that may have lead to metastasis. also, metastatic samples from icb naive patients would be collected and compared with those from icb treated patients to find out if the metastasis in treated patients was due to development of reistance.


Eligibility criteria:
inclusion criteria: * eligible patients will include retrospectively identified patients with rcc or uc who have received treatment with icb and achieved clinical benefit but subsequently developed a solitary new/progressive lesion that was removed surgically. patients with other tumor types who otherwise meet criteria may be included at a later time * additionally, a group of patients with rcc who have undergone a metastasectomy but who did not receive treatment with icb will be identified. these patients may be approached for study participation to serve as a comparator group exclusion criteria: -
participation restrictions in breast cancer survivors

Conditions: Breast Cancer

Summary: this project will develop and preliminarily evaluate an intervention to assist young-middle adult rural breast cancer survivors to overcome functional impairments related to their cancer treatment. younger breast cancer survivors (below age 60) have ongoing family, social and vocational responsibilities and recreational interests and are at increased risk of developing long-term difficulties performing these valued activities (participation restrictions). rural cancer survivors are medically underserved and due to distance and geographic isolation face significant barriers to accessing traditional rehabilitation services. alternative rehabilitation approaches are sorely needed for this population. based on previous research with cancer and other medical populations a working draft of a treatment manual using a telephone-delivered behavioral activation and problem solving (ba/ps) intervention has been designed. prior to testing the intervention in a randomized clinical trial, additional work must be completed. the specific aims of this study are to a. refine the ba/ps treatment manual, b. develop and apply treatment integrity measures for the ba/ps manual, c. assess participation restrictions and associated outcomes, d. preliminarily assess the immediate and maintenance effects of ba/ps, and e. examine mediators and moderators of ba/ps effects based on our "self regulation" model of functional recovery. 188 young-middle adult breast cancer survivors will be screened for participation restrictions following cancer treatment and 40 survivors with participation restrictions will receive ba/ps delivered by phone. ba/ps participants will be assessed for treatment effectiveness and interviewed regarding their experiences during treatment to provide information for refining the manual. the long-term objective of this line of research is to develop effective and feasible treatments for the medical and psychosocial consequences of cancer and its treatment in medically underserved cancer survivors (e.g., rural populations).


Eligibility criteria:
inclusion criteria: 1. female breast cancer patient stages i-iii. 2. age 18-59. 3. completion of definitive breast cancer treatment (i.e., subsequent to loco-regional surgical treatment and completion of adjuvant or neo-adjuvant chemotherapy with or without radiation) within the past 3-6 months. 4. screen positive for a moderate or worse level of participation restriction (work and social adjustment scale score \> 10) within 6 months following cancer treatment. 5. english speaking. 6. have a land-based phone or reliable cell phone reception. exclusion criteria: 1. non-correctable hearing loss. 2. moderate-severe cognitive impairment indicated by a score \< 3 on a 6-item cognitive screener. 3. medical record documentation of severe mental illness (i.e., schizophrenia or bipolar disorder) or active substance abuse. 4. medical record documentation of a physical disorder with associated functional impairment (e.g., parkinson's disease, stroke, congestive heart failure, etc.).
safety and efficacy in patients treated for hip or knee pji with vancomycin and tobramycin joint irrigation

Conditions: Prosthetic Joint Infection

Summary: study type prospective, single-arm, open-label, multicenter (3 to 5 sites), interventional trial. primary study objective the objective of the study is to determine the safety profile of local antibiotic irrigation for the treatment of pji. primary outcome measure the overall safety profile is characterized by assessing the incidence of adverse events (aes), serious adverse events (saes), suspected adverse reactions, adverse reactions, and unexpected adverse reactions. follow-up patients will be assessed for all measures at 3 weeks, 6 weeks, 12 weeks, and 12 months from initial surgery.


Eligibility criteria:
inclusion criteria: * age ≥18 years or greater * preoperative diagnosis of pji of the hip or knee per the 2018 definition of periprosthetic hip and knee infection * chronic pji (symptoms lasting at least 4 weeks) per tsukayama et al. * medical clearance for surgery * physical and mental ability and willingness to comply with the protocol, including the ability to read and complete required forms, and willingness and ability to adhere to the scheduled follow-up visits and requirements of the protocol exclusion criteria: * late acute hematogenous infection per tsukayama et al. * patients for whom a two-stage exchange arthroplasty is not indicated * sepsis * previously failed single- or two-stage revision arthroplasty for pji (aseptic revision, polyethylene liner exchange, and/or irrigation and debridement with component retention is allowed) * patients with pji of more than one joint * patients on chronic antibiotic therapy (≥ 6 months duration) * patients who require therapeutic anticoagulation * patients on antiplatelet therapy for whom withholding antiplatelet therapy for any amount of time is contraindicated * patients with renal insufficiency/failure (serum creatinine ≥ 2.0 mg/dl) * patients with uncontrolled diabetes, defined as: hemoglobin a1c levels \> 8.0% * patients on immunosuppressive therapy, chemotherapy for malignant disease, or glucocorticoid therapy (e.g. prednisone ≥ 10 mg/day). * patients with immunodeficiency (e.g., splenectomy; sickle cell anemia; stage 3 hiv; primary humoral, bone marrow, or other transplantation.) * anticipated or potential patient relocation that may interfere with follow-up examinations * allergy to vancomycin hcl or tobramycin sulfate (note: prior history of red man's syndrome is not considered an allergy) * patients who are pregnant or planning to become pregnant * patients in whom negative pressure wound therapy is contraindicated * patients infected with pathogens that are not considered susceptible to vancomycin hcl or tobramycin sulfate, as per the investigator's opinion * breastfeeding at screening visit * patients who are prisoners * participation in another clinical trial of another investigational drug or investigational device within the past 30 days

Keywords: hip knee biofilm minimum-biofilm-eradication-concentration
antiepileptic drug carbamazepine in treatment of bronchial asthma

Conditions: Bronchial Asthma

Summary: the purpose of this study was evaluation the efficacy of antiepileptic drug carbamazepine in the treatment of mild-to-severe bronchial asthma.

effective therapy of asthma still remains quite serious problem. according current opinion of leading specialists, asthma is an inflammatory disorder. but asthma also is a paroxysmal disorder: many specialists underline paroxysmal clinical picture of asthma. according to some authors, neurogenic inflammation may play important role in asthma mechanism. but migraine and trigeminal neuralgia are also neurogenic inflammatory paroxysmal diseases, and some antiepileptic drugs, like carbamazepine and valproates, are very effective in therapy of these diseases - more than in 80% of cases. if bronchial asthma also is paroxysmal inflammatory disease, we can suppose a possibility that some antiepileptic drugs also may show high efficacy in asthma therapy. taken in consideration this hypothesis, we performed a double-blind, placebo-controlled 3-month trial for evaluation of carbamazepine efficacy in treatment of patients with mild-to-severe bronchial asthma. comparison: patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.

Eligibility criteria:
inclusion criteria: * out patients * bronchial asthma has been known at least for 1 year * absence of long-term remissions of asthma (lasting more than 1 month) * poorly controlled asthma, due to various reasons * non-smokers exclusion criteria: * presence of concomitant acute or chronic severe diseases * abnormal baseline haematology, blood chemistry or urinalysis * allergy or adverse reactions to investigational drug * age younger than 16 years old * long-term history of smoking * pregnancy or lactating

Keywords: bronchial asthma carbamazepine efficacy
oxidative stress markers in open and laparoscopic colectomy for cancer

Conditions: Colorectal Cancer

Summary: contribution to the study of oxidative stress markers in laparoscopic vs open colectomy for colorectal cancer


Eligibility criteria:
inclusion criteria: * colorectal cancer exclusion criteria: * metastases * recurrent disease * chronic diseases

Keywords: lipid peroxidation protein peroxidation dna peroxidation rna peroxidation cytokines hscrp oxidative stress markers open surgery laparoscopic surgery
non-operative vs. operative management of acute appendicitis in vulnerable patient populations

Conditions: Acute Appendicitis

Summary: the overall project goal is to conduct a pilot randomized clinical trial of operative (laparoscopic appendectomy) vs nonoperative (antibiotic) management of uncomplicated acute appendicitis for vulnerable populations. specifically, the elderly, non-english speakers, and those with economic vulnerability (low socioeconomic status and/or manual labor jobs without a non-weight lifting aspect), are three vulnerable population subsets identified. this pilot trial will provide critical preliminary data for planning and conducting a larger multi-site randomized trial.

the study would involve consented subjects, once confirmed eligible to proceed after screening, will be randomly assigned to two arms: * group 1 - operative group - operation will be performed to remove appendix. * group 2 - non-operative group - no operation will be performed, and instead the subject will receive intra-venous (iv) antibiotics, transitioned to by mouth (oral) antibiotics, for treatment of appendicitis. aside from the routine hospital care, participants will be asked to fill out a survey for cognitive function (cam assessment form), pain (visual analog scale), and quality of life at the start and end of participant's hospital stay, 1-2 weeks after discharge, and again at 6 weeks after discharge from the initial hospital visit. participants will also be asked to participate in a qualitative interview, either by virtual visit, site visit, or phone call, at 1-2 weeks and again at about 6 weeks after discharge from the hospital. each interview will be approximately 20-30 minutes of the participant's time.

Eligibility criteria:
inclusion criteria: * age ≥18 years * able to consent for the study * diagnosis of acute appendicitis confirmed by ct imaging exclusion criteria: * appendicolith/fecalith on imaging * chronic or recurrent appendicitis * having received prior antibiotic treatment for other reasons within 5 days prior to study enrollment * hemodynamically abnormal (sbp\ 120, mmhg, partial pressure of oxygen in arterial blood (pao2\<60), or potential of hydrogen (ph\<7.3)). * inability to tolerate general anesthesia (determined by surgery and anesthesiology teams)
retrospective analysis of the outcome of patients with relapsed/refractory acute myeloid leukemia included in a patient named program of gemtuzumab ozogamicin/mylotarg®

Conditions: Leukemia, Myeloid, Acute

Summary: gemtuzumab ozogamicin/mylotarg® (go) is a conjugate of a derivative of calicheamicin a potent antitumor anthracycline antibiotic linked to a recombinant humanized antibody against the cd33 antigen. pivotal phase 2 study in relapsed aml adult patients used go 9 mg/m2 as a monotherapy on days 1 and 14, and showed a 30% response rate with half cr and crp (cr with incomplete platelets recovery). four randomized studies, 3 in adults and 1 in children, performed in patients with non-previously treated aml tested the addition of lower doses of go ( 3mg or 6 mg/m2) to standard induction chemotherapy and showed benefit on survival endpoints. results from these studies were available in 2011 in adults and 2014 in children. in 2010 the french health agency (ansm) opened a compassionate patient named program (authorization for temporary utilization (atu) program) of go in relapsed/refractory aml patients. patients were orally informed about the status of the go. from 2010 to 2012 it was recommended to use go as a monotherapy at a dose of 9mg/m2 on days 1 and 14 according to the protocol used in pivotal phase 2 study. after 2012 it was recommended by the health authority to use go at the dose of 3 or 6 mg/m2 in addition to chemotherapy regarding the toxicity of higher dose given once. from 2010 to 2015 more than 500 aml patients have been included in this atu program. the main objective of the study presented here is to assess the efficacy and safety of go 3 or 6 mg/m2 (single dose or fractionated go) given in as treatment of relapsed/refractory aml in adult patients. the coordinator choose to collect the data from centers that included 10 patients or more from january 2012 to december 2015. this represents approximately 420 patients from 33 hematology departments.


Eligibility criteria:
inclusion criteria: * patient more than 18 year old; * de novo or secondary leukemia. * refractory to standard intensive chemotherapy (defined by the association of anthracycline and cytarabine, at different doses) or in first relapse. * treated with go from january 2012 to december 2016. exclusion criteria: * previous treatment with go * aml type 3 * more than 1 relapse
a study to evaluate indocyanine green lymphangiography to improve lymphadenectomy in gastric cancer patients

Conditions: Gastric Cancer

Summary: this study will be looking at the safety and added benefit of using the indocyanine green dye (icg) during surgery.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 and ≤ 75 years of age. * primary gastric adenocarcinoma of any histological subtype confirmed pathologically by endoscopic biopsy. * clinical stage tumor t1-4a (ct1-4a), n -/+, m0 at preoperative evaluation according to the american joint committee on cancer (ajcc) cancer staging manual seventh edition. * no distant metastasis, no direct invasion of adjacent organs such as pancreas and spleen in preoperative exams. * american society of anesthesiology score (asa) class i, ii, or iii. * written informed consent. exclusion criteria: * patients ≤ 18 and ≥ 75 years of age. * history of previous upper abdominal surgery (except laparoscopic cholecystectomy). * history of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection. * history of allergy to iodine agents. * history of other malignant disease within past five years. * emergency surgery due to complication caused by gastric cancer, such as bleeding obstruction or perforation. * patients intraoperatively/postoperatively confirmed as t4b. * patients intraoperatively confirmed as unable to complete d2 lymph node dissection or r0 dissection.